MannKind’s Future Uncertain After Sanofi Terminates Afrezza Deal
This article was originally published in The Pink Sheet Daily
During a very brief investor call, MannKind says it is planning to change its pricing and contracting tactics, after being left in the lurch as Sanofi terminates its development and commercialization deal on the inhaled insulin Afrezza.
You may also be interested in...
FDA’s unusually specific request suggests continued worries about safety of MannKind’s inhalable insulin; large trial (8,000-10,000 type 2 diabetics) has a variety of goals.
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.